Shareholders' Equity, Securities Purchase Agreement and Share-based Compensation (Details)		12 Months Ended		21 Months Ended
	Nov. 03, 2016 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) Plan $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2015 USD ($) $ / shares shares
Securities Purchase Agreement [Abstract]
Common stock issued (in shares)		60,905,666	60,436,548
Net proceeds from common stock issuance | $		$ 0	$ 23,428,900
Accelmed [Member]
Securities Purchase Agreement [Abstract]
Common stock issued (in shares)	16,129,033
Common stock issued price (in dollars per share) | $ / shares	$ 1.55
Gross proceeds from common stock issuance | $	$ 25,000,000
Net proceeds from common stock issuance | $	23,429,000
Common stock issuance expense | $	$ 1,571,000
Stock Options [Member]
Weighted-average assumptions used to value the options granted [Abstract]
Expected life, in years		3 years	3 years 10 months 24 days
Risk-free interest rate		1.45%	0.98%
Expected volatility		66.89%	61.86%
Expected dividend yield		0.00%	0.00%
Stock options, number of shares [Roll Forward]
Outstanding, beginning of period (in shares)		1,680,990	2,573,640
Options granted (in shares)		1,042,809	692,400
Options exercised (in shares)		(7,211)	0
Options surrendered (in shares)		(170,625)	(1,585,050)
Outstanding, end of period (in shares)		2,545,963	1,680,990	2,573,640
Exercisable, end of period (in shares)		1,031,731
Stock options, weighted average exercise price [Roll Forward]
Outstanding, beginning of period (in dollars per share) | $ / shares		$ 3.54	$ 4.46
Options granted (in dollars per share) | $ / shares		1.65	1.05
Options exercised (in dollars per share) | $ / shares		1.35
Options surrendered (in dollars per share) | $ / shares		4.36	3.90
Outstanding, end of period (in dollars per share) | $ / shares		2.72	3.54	$ 4.46
Exercisable, end of period (in dollars per share) | $ / shares		4.55
Stock options, additional disclosures [Abstract]
Weighted-average grant date fair value (in dollars per share) | $ / shares		$ 0.74	$ 0.49
Outstanding, Aggregate intrinsic value, beginning of period | $		$ 752,290	$ 0
Exercised, Aggregate intrinsic value | $		13,001
Outstanding, Aggregate intrinsic value, end of period | $		3,243,914	$ 752,290	$ 0
Exercisable, Aggregate intrinsic value, end of period | $		$ 705,799
Outstanding, Weighted average remaining life in years		6 years 1 month 17 days	6 years 6 months 18 days	5 years 2 months 26 days
Options exercisable, Weighted average remaining life in years		3 years 4 months 20 days
Stock Options [Member] | Executive Employees and Directors [Member]
Weighted-average assumptions used to value the options granted [Abstract]
Forfeiture rate			15.00%
Stock Options [Member] | Non-Executive Employees [Member]
Weighted-average assumptions used to value the options granted [Abstract]
Forfeiture rate			20.00%
2015 Plan [Member]
Securities Purchase Agreement [Abstract]
Number of active plans for share-based compensation grants | Plan		1
Number of shares reserved for share-based grants (in shares)		2,500,000
Shares remain available for grant (in shares)		139,738
Vesting period		2 years
2015 Plan [Member] | Stock Options [Member]
Securities Purchase Agreement [Abstract]
Vesting period		3 years
Stock options, number of shares [Roll Forward]
Outstanding, end of period (in shares)		2,545,963
2015 Plan [Member] | Stock Options [Member] | Minimum [Member]
Securities Purchase Agreement [Abstract]
Term of share-based payment award		7 years
2015 Plan [Member] | Stock Options [Member] | Maximum [Member]
Securities Purchase Agreement [Abstract]
Term of share-based payment award		10 years